Literature DB >> 24552324

Bevacizumab in glioblastoma--still much to learn.

Howard A Fine1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24552324     DOI： 10.1056/NEJMe1313309

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  23 in total

1.  Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.

Authors:  Seymur Gahramanov; Csanad Varallyay; Rose Marie Tyson; Cynthia Lacy; Rongwei Fu; Joao Prola Netto; Morad Nasseri; Tricia White; Randy L Woltjer; Sakir Humayun Gultekin; Edward A Neuwelt
Journal:  CNS Oncol       Date:  2014-11

2.  Management of high-grade gliomas in the pediatric patient: Past, present, and future.

Authors:  Magimairajan Issai Vanan; David D Eisenstat
Journal:  Neurooncol Pract       Date:  2014-09-12

3.  Should the subventricular zone be part of the "rad" zone?

Authors:  Benjamin W Corn; Jeffrey Raizer; Andrew A Kanner
Journal:  J Neurooncol       Date:  2014-05-23       Impact factor: 4.130

4.  Normalizing Tumoral Vessels to Treat Cancer: An Out-of-the-Box Strategy Involving TIE2 Pathway.

Authors:  Juan Fueyo; Mohammad B Hossain; Teresa Nguyen; Candelaria Gomez-Manzano
Journal:  Transl Cancer Res       Date:  2017-03       Impact factor: 1.241

5.  Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism.

Authors:  Rasha Elmghirbi; Tavarekere N Nagaraja; Stephen L Brown; Swayamprava Panda; Madhava P Aryal; Kelly A Keenan; Hassan Bagher-Ebadian; Glauber Cabral; James R Ewing
Journal:  Radiat Res       Date:  2016-12-21       Impact factor: 2.841

Review 6.  The Microenvironmental Landscape of Brain Tumors.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

7.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Authors:  Thomas Sandmann; Richard Bourgon; Josep Garcia; Congfen Li; Timothy Cloughesy; Olivier L Chinot; Wolfgang Wick; Ryo Nishikawa; Warren Mason; Roger Henriksson; Frank Saran; Albert Lai; Nicola Moore; Samir Kharbanda; Franklin Peale; Priti Hegde; Lauren E Abrey; Heidi S Phillips; Carlos Bais
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

8.  Acetate is a bioenergetic substrate for human glioblastoma and brain metastases.

Authors:  Tomoyuki Mashimo; Kumar Pichumani; Vamsidhara Vemireddy; Kimmo J Hatanpaa; Dinesh Kumar Singh; Shyam Sirasanagandla; Suraj Nannepaga; Sara G Piccirillo; Zoltan Kovacs; Chan Foong; Zhiguang Huang; Samuel Barnett; Bruce E Mickey; Ralph J DeBerardinis; Benjamin P Tu; Elizabeth A Maher; Robert M Bachoo
Journal:  Cell       Date:  2014-12-18       Impact factor: 41.582

Review 9.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

Review 10.  Current status and future directions of anti-angiogenic therapy for gliomas.

Authors:  Wolfgang Wick; Michael Platten; Antje Wick; Anne Hertenstein; Alexander Radbruch; Martin Bendszus; Frank Winkler
Journal:  Neuro Oncol       Date:  2015-10-12       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.